CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.

  • CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira.

  • It will be priced more than 80% lower than the current list price of Humira, which is made by drugmaker Abbvie.

  • CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.

  • JasSmith@kbin.social
    15·
    10 months ago

    Cost Plus Drugs is really lighting a fire under the assess of the medication industry in the U.S. Bravo, Cuban.

  • IHeartBadCode@kbin.social
    7·
    10 months ago

    Just FYI for semantics. Generics is a term usually for small molecular weight compounds, usually under 900 daltons. Biosimilars is the term for higher molecular weight.

    Doing generics is a lot simpler than biosimilars, in both you must wait for the patient to run out. But biosimilars are less likely to be made using an alternative process than the original trade secret process. This is due in part to the higher molecular weight which means a more complex compound.